| Followers | 232 |
| Posts | 26887 |
| Boards Moderated | 0 |
| Alias Born | 01/12/2013 |
Tuesday, August 06, 2019 12:22:43 PM
Janet-
ICER understated the value of Vascepa and it certainly doesn’t highlight the overall costs savings in healthcare to the US as a whole, but ICER is correct the drug is underpriced.
Vascepa’s estimated net price ($1,600-2,000) falls below ICER‘s estimated price of $3,400 – $6,200 required to achieve their $50,000 to $100,000 QALY threshold — and nearly 100% of iterations met the $50,000 threshold, noted Jefferies’ Michael Yee. “(H)ence Vascepa is possibly “underpriced” relative to the key benefit thresholds used by ICER.”
https://endpts.com/icer-backs-cost-effectiveness-of-vascepa-xarelto-epizymes-lead-drug-wins-speedy-us-review/
Please expedite the “Priority Review”; as you are well aware, in my opinion label expansion is 6 years overdue. Additionally, it would be helpful for the FDA to finally include Vascepa into full “Program” status, there’s been significant monetary damages done directly due to the FDA not abiding by the Moss Federal Court decision.
https://investor.amarincorp.com/static-files/512592f8-f7c1-43ed-abf6-5523e6d1e3fe
The FDA should consider posting comments to ICER review regarding the understated value placed on deaths, and absent data on revascularization procedures and hospitalization for unstable angina.
Thank you for the consideration
Woodcock/FDA/Senate HELP & Amarin are fully aware I file my HHS complaint after R-I label, any further delays are unexceptional. Delays have caused increased CV deaths and wasted Billions in healthcare. Amarin raised enough cash to take any further delays out of FDA hands and that’s great strategy.
Brilliant timing on FDA FOIA requests, FDA can’t slow roll requests because they need to cover their asses and expose the industry influence just prior to ANCHOR SPA.
BB
If you're not good at being yourself, then maybe that's being yourself!
Recent AMRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
